上海弼领生物技术

Biling Bio is a Shanghai-based biotechnology company specializing in the development of next-generation Antibody-Drug Conjugates (ADCs) and Peptide-Drug Conjugates (PDCs). The company utilizes its proprietary Biling-Link platform to engineer site-specific, stable, and highly potent conjugates aimed at improving the therapeutic index for cancer patients. Founded in 2021 by Dr. Jidong Zhang, an expert in biologics development, Biling Bio focuses on creating a diverse pipeline of precision medicines for solid tumors. The firm has secured significant backing from leading venture capital firms to accelerate its transition from discovery to clinical-stage operations. Their approach emphasizes overcoming the limitations of traditional conjugation methods to deliver more consistent and effective clinical outcomes. By integrating advanced linker-payload technologies with novel targeting moieties, Biling Bio aims to address high unmet medical needs in the oncology space.